FibroScan® by echosens
The non-invasive solution for comprehensive management of liver health
Although NAFLD is the most common chronic liver disease worldwide, early intervention can reverse liver damage and improve patient outcomes.
Identifying patients with advanced fibrosis (F≥3 according to NASH CRN scoring system) is key for the management of patients with NALFD since they are at increased risk of developing liver-related complications.
Agile 3+ combines LSM by VCTE™ with easily accessible blood biomarkers (AST, ALT, Platelets) to help in the identification of advanced fibrosis in NAFLD patients with optimized Positive Predictive values compared to LSM alone and help in the prediction of liver complications.
High clinical performances demonstrated in large external validation cohorts from different geographical origins.
Peer reviewed paper under submission
Sanyal et al., Enhanced diagnosis of advanced fibrosis and cirrhosis in non-alcoholic fatty liver disease patients with FibroScan®-based Agile scores
A novel noninvasive score including LSM by VCTE and routine clinical parameters improves the identification of advanced fibrosis among patients with NAFLD and may reduce the necessity of liver biopsy in this patient population. In addition, external validation on primary and secondary care centers could assess its potential as a new tool to refer patients to liver specialists.
Agile 3+ and Agile 4 well predict the occurrence of liverrelated events in patients with NAFLD. Particularly, rule-in cut-offs of both scores better identify at-risk patients than LSM alone. These results demonstrate the interest of those scores in the identification of patients requiring hepatocellular carcinoma and esophageal varices screening.
Agile 3+ is a non-device Clinical Decision Support (CDS) that meets the criteria outlined in section 520(o)(1)(E) of the FD&C Act. Agile 3+ calculator is a tool for clinicians, computed from LSM (obtained from FibroScan® device), AST, ALT, platelets, diabetes status, age and gender, to aid in the identification of patients with suspicion of NAFLD as having advanced fibrosis. It was developed based on a pool of retrospective cohorts and published in peer-reviewed literature. Agile 3+ is presented as an educational service intended for licensed healthcare professionals. While this score is about specific medical and health issues, it is not a substitute for or a replacement of personalized medical advice and is not intended to be used as the sole basis for making individualized medical or health-related decisions.